Keybank National Association OH Has $2.90 Million Stock Holdings in Lantheus Holdings, Inc. $LNTH

Key Points

• KeyBank cut its position in Lantheus by 76.7%, selling 143,395 shares and leaving it with 43,631 shares valued at about $2.90 million (≈0.07% of the company).
• Lantheus beat expectations for the quarter with $1.67 EPS vs. $1.17 consensus and $406.8M revenue vs. $367.0M, and set FY2026 guidance of $5.00–$5.25 EPS.
• Analyst sentiment is broadly positive (eight Buys, three Holds; consensus price target $88.86, rated a Moderate Buy), and institutional investors hold about 99.06% of the stock.

Keybank National Association OH cut its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 76.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 43,631 shares of the medical equipment provider's stock after selling 143,395 shares during the period. Keybank National Association OH owned 0.07% of Lantheus worth $2,904,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of LNTH. Hantz Financial Services Inc. increased its stake in shares of Lantheus by 412.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 396 shares during the last quarter. First Horizon Corp acquired a new position in shares of Lantheus during the 3rd quarter worth about $26,000. Osterweis Capital Management Inc. acquired a new position in shares of Lantheus during the 2nd quarter worth about $36,000. Farther Finance Advisors LLC increased its stake in shares of Lantheus by 71.4% during the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider's stock worth $44,000 after purchasing an additional 275 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Lantheus during the 3rd quarter worth about $55,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Stock Performance

Shares of LNTH stock opened at $85.50 on Friday. The company has a market capitalization of $5.57 billion, a price-to-earnings ratio of 25.37 and a beta of -0.12. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.51 and a current ratio of 2.70. The company has a 50-day simple moving average of $78.85 and a 200 day simple moving average of $68.02. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $108.91.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, topping the consensus estimate of $1.17 by $0.50. The business had revenue of $406.79 million during the quarter, compared to the consensus estimate of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. Lantheus's revenue was up 4.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.59 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, sell-side analysts predict that Lantheus Holdings, Inc. will post 4.29 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on LNTH shares. Citizens Jmp lifted their target price on shares of Lantheus from $73.00 to $78.00 and gave the stock a "market outperform" rating in a report on Tuesday, February 24th. Mizuho lifted their target price on shares of Lantheus from $85.00 to $95.00 and gave the stock an "outperform" rating in a report on Monday, April 13th. Citigroup reaffirmed an "outperform" rating on shares of Lantheus in a report on Tuesday, February 24th. Truist Financial lifted their target price on shares of Lantheus from $89.00 to $98.00 and gave the stock a "buy" rating in a report on Wednesday, April 15th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a $110.00 target price on shares of Lantheus in a report on Tuesday, March 17th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $88.86.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company's portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.